Genmab — Director's Dealing 2015

Dec 10, 2015

Company Announcement

Copenhagen, Denmark; December 10, 2015 – In accordance with Section 28a of the
Danish Securities Trading Act, the company’s board members and executives have
given Genmab A/S (Nasdaq Copenhagen: GEN) power of attorney on their behalf to
publish trading in Genmab shares and related instruments by the company’s board
members, executives and their related parties, as follows:

Name: Mats Pettersson
Reason: Chairman of the Board of Directors
Issuer: Genmab A/S
ID code/ISIN: DK0010272202
Description: Restricted Stock Units
Transaction: Grant
Trading date: December 10, 2015
Market: Nasdaq Copenhagen A/S
Number: 957
Value: DKK 899,101.50

Name: Anders Gersel Pedersen
Reason: Member of the Board of Directors
Issuer: Genmab A/S
ID code/ISIN: DK0010272202
Description: Restricted Stock Units
Transaction: Grant
Trading date: December 10, 2015
Market: Nasdaq Copenhagen A/S
Number: 718
Value: DKK 674,561

Name: Pernille Erenbjerg
Reason: Member of the Board of Directors
Issuer: Genmab A/S
ID code/ISIN: DK0010272202
Description: Restricted Stock Units
Transaction: Grant
Trading date: December 10, 2015
Market: Nasdaq Copenhagen A/S
Number: 478
Value: DKK 449,081

Name: Nedjad Losic
Reason: Member of the Board of Directors
Issuer: Genmab A/S
ID code/ISIN: DK0010272202
Description: Restricted Stock Units
Transaction: Grant
Trading date: December 10, 2015
Market: Nasdaq Copenhagen A/S
Number: 478
Value: DKK 449,081

Name: Burton G. Malkiel
Reason: Member of the Board of Directors
Issuer: Genmab A/S
ID code/ISIN: DK0010272202
Description: Restricted Stock Units
Transaction: Grant
Trading date: December 10, 2015
Market: Nasdaq Copenhagen A/S
Number: 478
Value: DKK 449,081

Name: Paolo Paoletti
Reason: Member of the Board of Directors
Issuer: Genmab A/S
ID code/ISIN: DK0010272202
Description: Restricted Stock Units
Transaction: Grant
Trading date: December 10, 2015
Market: Nasdaq Copenhagen A/S
Number: 478
Value: DKK 449,081

Name: Tom Vink
Reason: Member of the Board of Directors
Issuer: Genmab A/S
ID code/ISIN: DK0010272202
Description: Restricted Stock Units
Transaction: Grant
Trading date: December 10, 2015
Market: Nasdaq Copenhagen A/S
Number: 478
Value: DKK 449,081

Name: Jan G. J. van de Winkel
Reason: President & Chief Executive Officer
Issuer: Genmab A/S
ID code/ISIN: DK0010272202
Description: Restricted Stock Units
Transaction: Grant
Trading date: December 10, 2015
Market: Nasdaq Copenhagen A/S
Number: 11,387
Value: DKK 10,698,086.50

Name: David A. Eatwell
Reason: Executive Vice President & Chief Financial Officer
Issuer: Genmab A/S
ID code/ISIN: DK0010272202
Description: Restricted Stock Units
Transaction: Grant
Trading date: December 10, 2015
Market: Nasdaq Copenhagen A/S
Number: 7,693
Value: DKK 7,227,573.50

About Genmab
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated antibody therapeutics for the
treatment of cancer. Founded in 1999, the company has two approved antibodies,
Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia
indications and DARZALEX™ (daratumumab) for the treatment of heavily pretreated
or double refractory multiple myeloma. Daratumumab is in clinical development
for additional multiple myeloma indications and for non-Hodgkin’s lymphoma.
Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's
technology base consists of validated and proprietary next generation antibody
technologies - the DuoBody® platform for generation of bispecific antibodies,
and the HexaBody® platform which creates effector function enhanced antibodies.
The company intends to leverage these technologies to create opportunities for
full or co-ownership of future products. Genmab has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™;
the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody®
and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates.
DARZALEX™ is a trademark of Janssen Biotech, Inc.

Company Announcement no. 64
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark